Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-United
jRCT2011240042Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jan 2025
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing daplusiran/tomligisiran followed by bepirovirsen with placebo followed by bepirovirsen (2 arms). Primary endpoint: Functional cure after discontinuation of all chronic HBV treatments. Started Jan 2025; status: active, not recruiting.
02
Drugs
tomligisiranbepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2011240042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240042.